Synthesis of Bioactive Silver Nanoparticles Using New Bacterial Strains from an Antarctic Consortium

In this study, we report on the synthesis of silver nanoparticles (AgNPs) achieved by using three bacterial strains Rhodococcus , Brevundimonas and Bacillus as reducing and capping agents, newly isolated from a consortium associated with the Antarctic marine ciliate Euplotes focardii . After incubat...

Full description

Bibliographic Details
Published in:Marine Drugs
Main Authors: Maria Sindhura John, Joseph Amruthraj Nagoth, Kesava Priyan Ramasamy, Alessio Mancini, Gabriele Giuli, Cristina Miceli, Sandra Pucciarelli
Format: Article in Journal/Newspaper
Language:English
Published: MDPI AG 2022
Subjects:
Online Access:https://doi.org/10.3390/md20090558
https://doaj.org/article/762502f6018246a98a0c55331e07e073
Description
Summary:In this study, we report on the synthesis of silver nanoparticles (AgNPs) achieved by using three bacterial strains Rhodococcus , Brevundimonas and Bacillus as reducing and capping agents, newly isolated from a consortium associated with the Antarctic marine ciliate Euplotes focardii . After incubation of these bacteria with a 1 mM solution of AgNO 3 at 22 °C, AgNPs were synthesized within 24 h. Unlike Rhodococcus and Bacillus , the reduction of Ag + from AgNO 3 into Ag 0 has never been reported for a Brevundimonas strain. The maximum absorbances of these AgNPs in the UV-Vis spectra were in the range of 404 nm and 406 nm. EDAX spectra showed strong signals from the Ag atom and medium signals from C, N and O due to capping protein emissions. TEM analysis showed that the NPs were spherical and rod-shaped, with sizes in the range of 20 to 50 nm, and they were clustered, even though not in contact with one another. Besides aggregation, all the AgNPs showed significant antimicrobial activity. This biosynthesis may play a dual role: detoxification of AgNO 3 and pathogen protection against both the bacterium and ciliate. Biosynthetic AgNPs also represent a promising alternative to conventional antibiotics against common nosocomial pathogens.